Niagen Bioscience to Present at Two High-Profile Investor Conferences
Event summary
- Niagen Bioscience (NASDAQ: NAGE) will participate in two investor conferences in May 2026.
- CFO Ozan Pamir will present at the Sohn Investment Conference on May 12, 2026.
- CEO Rob Fried and CFO Ozan Pamir will hold one-on-one meetings at the Benchmark Consumer Conference on May 19, 2026.
- Niagen is the global leader in NAD+ science and healthy-aging research.
The big picture
Niagen Bioscience's participation in the Sohn Investment Conference and Benchmark Consumer Conference underscores its strategic focus on engaging with investors and analysts to highlight its leadership in NAD+ science. The company's robust patent portfolio and clinical product offerings position it as a key player in the healthy-aging market, which is increasingly attracting significant investment. The conferences provide a platform for Niagen to showcase its innovative solutions and potentially attract new partnerships or investment opportunities.
What we're watching
- Market Positioning
- How Niagen's participation in high-profile investor conferences will affect its market positioning in the competitive healthy-aging sector.
- Investor Sentiment
- Whether the company can sustain investor interest and momentum following these conferences.
- Product Expansion
- The pace at which Niagen can expand its product portfolio beyond Tru Niagen and Niagen Plus.
Related topics